Get the Stockscreener App
0.9318
3.82%
-0.0353
Adicet Bio Inc stock is traded at $0.9318, with a volume of 157.13K.
It is down -3.82% in the last 24 hours and down -37.57% over the past month.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
See More
Previous Close:
$0.9671
Open:
$0.9667
24h Volume:
157.13K
Relative Volume:
0.40
Market Cap:
$80.10M
Revenue:
$38.70M
Net Income/Loss:
$-142.66M
P/E Ratio:
-0.3426
EPS:
-2.72
Net Cash Flow:
$-98.18M
1W Performance:
-11.41%
1M Performance:
-37.57%
6M Performance:
-42.23%
1Y Performance:
-19.12%
1-Day Range:
$0.922
$0.9802
1-Week Range:
$0.925
$1.09
52-Week Range:
$0.925
$3.77
Adicet Bio Inc Stock (ACET) Company Profile
Name
Adicet Bio Inc
Sector
Industry
Phone
617-482-2333
Address
131 DARTMOUTH STREET, BOSTON
Compare ACET with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| ACET | 0.922 | 80.10M | 38.70M | -142.66M | -98.18M | -2.72 |
| VRTX | 446.52 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 741.51 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 592.50 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.90 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.19 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Adicet Bio Inc Stock (ACET) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-27-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-27-23 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-01-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Mar-31-22 | Initiated | SMBC Nikko | Outperform |
| Mar-08-22 | Initiated | Truist | Buy |
| Mar-04-22 | Initiated | Jefferies | Buy |
| May-18-21 | Initiated | BTIG Research | Buy |
| Apr-23-21 | Initiated | H.C. Wainwright | Buy |
| Apr-14-21 | Initiated | Canaccord Genuity | Buy |
| Apr-08-21 | Initiated | Guggenheim | Buy |
| Nov-04-20 | Initiated | B. Riley Securities | Buy |
| Oct-27-20 | Initiated | JMP Securities | Mkt Outperform |
| Oct-16-20 | Initiated | Wedbush | Outperform |
View All
Adicet Bio Inc Stock (ACET) Latest News
Adicet Bio Reports Q3 2024 Results and Clinical Progress - TipRanks
Adicet Bio (NASDAQ:ACET) Earns “Neutral” Rating from HC Wainwright - Defense World
First Patient Dosed in Trial for Adicet's T-Cell Therapy ADI-100 in Autoimmune Disease - CGTLive™
Adicet Bio To Present At Jefferies London Healthcare Conference; Webcast At 7:30 AM ET - Nasdaq
Adicet Bio Advances Cancer and Autoimmune Trials - TipRanks
Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma - Business Wire
Adicet Bio (NASDAQ:ACET) Receives Neutral Rating from HC Wainwright - MarketBeat
Adicet Bio begins lupus nephritis trial, eyes other diseases By Investing.com - Investing.com UK
Adicet Bio Launches Phase 1 Trial for Lupus Drug with FDA Fast Track Status | ACET Stock News - StockTitan
Is Adicet Bio (NASDAQ:ACET) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Adicet Bio's ADI-001 Shows Breakthrough CAR T Cell Results in Autoimmune Treatment Study | ACET Stock News - StockTitan
Adicet Bio amends loan terms with PacWest Bank By Investing.com - Investing.com Canada
RA Capital Management, L.P. Expands Stake in Adicet Bio Inc - GuruFocus.com
Adicet Bio To Present At Guggenheim Securities Healthcare Innovation Conference; Webcast At 3:00 PM - Nasdaq
FY2024 EPS Estimates for Adicet Bio Lowered by HC Wainwright - MarketBeat
HC Wainwright Decreases Earnings Estimates for Adicet Bio - Defense World
Wedbush Reiterates “Outperform” Rating for Adicet Bio (NASDAQ:ACET) - Defense World
Adicet Bio (NASDAQ:ACET) Announces Earnings Results, Hits Estimates - MarketBeat
Adicet Reports Third Quarter 2024 Financial Results and Provides Business Updates - StockTitan
Adicet Bio to Present at the American College of Rheumatology (ACR) Convergence 2024 - Business Wire
Adicet Bio to Present Breakthrough CAR T Cell Therapy at ACR Convergence 2024 | ACET Stock News - StockTitan
Adicet Bio to Participate in Upcoming Investor Conferences - Business Wire
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - StockTitan
HC Wainwright Reiterates Neutral Rating for Adicet Bio (NASDAQ:ACET) - Defense World
Adicet Bio shares maintain Neutral rating after FDA IND amendment - Investing.com India
Adicet Bio shares maintain Neutral rating after FDA IND amendment By Investing.com - Investing.com Australia
Adicet Bio Advances FDA-Approved Autoimmune Therapy Trials - Yahoo Finance
FDA greenlights Adicet Bio's trial expansion for autoimmune diseases - Investing.com
Adicet Bio Announces FDA Clearance of IND Amendment to Evaluate ADI-001 in Idiopathic Inflammatory Myopathy and Stiff Person Syndrome - StockTitan
Adicet Bio, Inc. (NASDAQ:ACET) Short Interest Down 11.0% in September - MarketBeat
Adicet Bio, Inc. (NASDAQ:ACET) Shares Bought by Cubist Systematic Strategies LLC - MarketBeat
Adicet Bio (NASDAQ:ACET) Raised to "Hold" at StockNews.com - MarketBeat
Millennium Management LLC Adjusts Stake in Adicet Bio Inc - GuruFocus.com
Renaissance Technologies LLC Has $1.83 Million Stock Holdings in Adicet Bio, Inc. (NASDAQ:ACET) - MarketBeat
Adicet Bio Inc’s Shares Reel: 36.70% Quarterly Revenue Decline Amid 122.78M Market Cap - The InvestChronicle
Did Adicet Bio Inc (ACET) perform well in the last session? - US Post News
Adicet Bio, Inc.'s (NASDAQ:ACET) large institutional owners must be happy as stock continues to impress, up 11% over the past week - Simply Wall St
Recent Insider Activity Suggests Potential Gains for Adicet Bio Inc (ACET) - Knox Daily
Adicet Bio stock maintains neutral rating amid lupus nephritis trial - Investing.com
Stonepine Capital Management LLC Has $737,000 Holdings in Adicet Bio, Inc. (NASDAQ:ACET) - Defense World
Adicet Bio begins enrolling subjects in Phase I trial of autoimmune disease therapy - Clinical Trials Arena
Stonepine Capital Management LLC Increases Stake in Adicet Bio, Inc. (NASDAQ:ACET) - MarketBeat
Adicet Bio to Present at the American Society of Gene & Cell Therapy’s (ASGCT) 2024 Advancing Gene + Cell Therapies for Cancer Conference - Business Wire
Adicet Bio (NASDAQ:ACET) Stock Rating Reaffirmed by HC Wainwright - MarketBeat
Adicet Bio (NASDAQ:ACET) Now Covered by Analysts at Guggenheim - MarketBeat
Guggenheim Begins Coverage on Adicet Bio (NASDAQ:ACET) - Defense World
Adicet Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases - BioSpace
Adicet Bio Launches Phase 1 Trial of ADI-001, Eyes Expansion - TipRanks
Wall Street SWOT: Adicet Bio stock navigates competitive CAR-T waters - Investing.com
Biomarker Data from Oncology Trial for Adicet Bio’s Gamma Delta T-cell Therapy ADI-001 Indicates Potential for Use in Autoimmune Disease - CGTLive™
Adicet Bio Inc Stock (ACET) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.42%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):